Tuesday, October 6, 2020 Daily Archives

Competition for CMOs drove inhouse investment, says Regenxbio

by

Regenxbio says increasing competition for capacity in the CMO space prompted the adoption of a hybrid gene therapy manufacturing strategy. Industry demand for contract manufacturing organizations (CMOs) with the technical skills required to manufacture gene therapies has increased in recent years. According to the Alliance for Regenerative Medicine, as of Q3 last year, 370 trials involving gene therapies were ongoing, which is an increase on the 351 underway in the equivalent period in 2018. Katie Masterson, director of manufacturing operations…

October 6, 2020

CellGenix: Serum-free medium offers faster T-cell therapy manufacturing

by

Freiburg, Germany-based CellGenix says its T-cell medium – CellGenix TCM – offers a serum-free and xeno-free alternative for rapid expansion of functional human T-cells. Due to stable glutamine in the formulation, the medium is ready-to-use for T-cell cultures without the need for supplementation with human serum or glutamine. Many current T-cell therapy protocols rely on the addition of human serum. Eliminating the use of human serum will reduce the failure rate in your manufacturing process due to the high lot-to-lot…

October 6, 2020

Fujifilm to use PNI tech to make nanoparticles for VLP’s COVID vaccine

by

VLP Therapeutics has hired Fujifilm Corp to help it manufacture its COVID-19 vaccine candidate for clinical trials. Under the deal, financial terms of which were not disclosed, Fujifilm will produce the lipid nanoparticle that is used to deliver the mRNA-based vaccine. The firm will also be involved in process and formulation development. The aim is to support efforts to move the vaccine into clinical trials. Mizuki Itou, a spokesperson for Fujifilm Holdings – Fujifilm Corp’s parent company – told us…

October 6, 2020